Researchers at The AIRC Institute of Molecular Oncology in Milan have discovered that the targetable enzyme phosphatidylinositol 5-phosphate 4-kinase type-2 β (PIP4K2B) participates in mechanosensing leading to changes in gene expression, nuclear morphology and cellular motility. The expression of PIP4K2B bodes a poor prognosis in cancer patients and PIP4K2B is the sole PIP4K isoform localized to the nucleus.
Medshine Discovery Inc. has prepared octahydropyrazinodiazanaphthyridine dione compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Acerand Therapeutics (Hong Kong) Ltd. has patented pyrimidine-containing dihydropyrazolone derivatives acting as Wee1-like protein kinase (Wee1) inhibitors and reported to be useful for the treatment of cancer.
Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.
Prodrugs of G protein-coupled receptor GPR52 agonists have been reported in a recent Heptares Therapeutics Ltd. patent as potentially useful for the treatment of psychosis, among others.
Arena Pharmaceuticals Inc. and Boehringer Ingelheim Pharma GmbH & Co. KG have jointly patented 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivative G protein-coupled receptor GPR52 agonists.
A recent study investigated the role of neuraminidase 1 (NEU1) in renal fibrosis. Researchers found increased levels of NEU1 in the fibrotic kidneys of patients and two mouse models of renal fibrosis (mice subjected to unilateral ureteral obstruction or administered folic acid).
Lygenesis Inc. and Imagine Pharma Inc. have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The collaboration will leverage Imagine Pharma’s type 1 diabetes activated islet progenitor cells (T1D AIPCs) and Lygenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes.
C-type lectin receptor is a family of molecules consisting of several proteins that recognize a broad spectrum of ligands, such as immunoreceptor tyrosine-based activation motif (ITAM) and immunoreceptor tyrosine-based inhibitory motif (ITIM), and are known to regulate diverse immunological functions.
Defence Therapeutics Inc. says it has successfully established a strategy conjugating mRNA molecules to Accum, the company’s core technology that enables precision delivery of vaccine antigens or antibody-drug conjugates in their intact form to target cells.
RSS
